Fabrizio Melfa

Dr. Fabrizio Melfa

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Fabrizio MelfaFabrizio Melfa
Fabrizio Melfa
AMAlec D McCarthy
Alec D McCarthy
SAShino Bay Aguilera
Shino Bay Aguilera
JLJani van Loghem
Jani van Loghem
Alessandro GennaiAlessandro Gennai
Alessandro Gennai
Background/Objectives: This retrospective observational study sought to determine the efficacy and safety of an innovative combined treatment protocol using guided Superficial Enhanced Fluid Fat Injection (SEFFI) and calcium hydroxylapatite (CaHA) in facial rejuvenation. Methods: A total of 158 patients (149 females and 9 males) underwent the combined treatment of guided SEFFI and diluted/hyperdiluted CaHA. The study evaluated treatment outcomes at 30, 90, and 150 days post-treatment using the Global Aesthetic Improvement Scale (GAIS) and three-dimensional photogrammetric analysis. Results: The combined treatment demonstrated consistent enhancement in skin quality and facial volume across temporal, malar, zygomatic, and jawline regions. At 90 days post-treatment, substantial improvements were observed, with the GAIS scores reflecting significant enhancements in both skin quality and volume, which were sustained or slightly improved by 150 days. Minor complications, predominantly ecchymosis at the injection sites, resolved within a week, confirming the treatments’ safety. Conclusions: The integration of guided SEFFI and CaHA resulted in significant improvements in skin quality and facial volume with minimal complications. Further research is recommended to consolidate these findings and explore long-term outcomes.

8 August 2023 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
Alessandro GennaiAlessandro Gennai
Alessandro Gennai
MBMonica Baldessin
Monica Baldessin
Fabrizio MelfaFabrizio Melfa
Fabrizio Melfa
BBBruno Bovani
Bruno Bovani
ACAlessandra Camporese
Alessandra Camporese
PTPiero Tesauro
Piero Tesauro
Background: The aging process starts in the center of the face, in the periocular region and around the mouth, with a combination of volume loss, tissue descent, deepened wrinkles, and the loss of skin structure and quality. Recently, several studies have demonstrated the efficacy of therapies based on autologous adipose tissue grafting, which leverages the properties of stromal vascular fraction (SVF) and adipose-derived mesenchymal stem cells (ADSCs) to accelerate the regenerative processes of the skin. This study aims to verify the ability of guided superficial enhanced fluid fat injection (SEFFI) in the facial area to correct volume loss and skin aging, proving that this standardized procedure has a very low rate of complications. Methods: We retrospectively collected data from 2365 procedures performed in Italian centers between 2019 and 2021. Guided SEFFI was performed alone or combined with cosmetic treatments, including the use of hyaluronic acid filler, suspension threads, synthetic calcium hydroxylapatite, botulin toxin, and microneedling. Results: guided SEFFI was used alone in more than 60% of the patients and in all facial areas. In about one-tenth of the patients, guided SEFFI was combined with a botulin toxin treatment or hyaluronic acid filling. Other procedures were used more rarely. Ecchymosis in the donor or injection sites was the most frequent adverse event but was only observed in 14.2% and 38.6% of the patients, respectively. Conclusions: The guided SEFFI technique is standardized and minimally invasive, leading to very few complications. It constitutes a promising antiaging medical treatment that combines effectiveness, safety, and simplicity.

9 August 2026 in Reports
Verified
Journal Article
Open access
PDF file
Fabrizio MelfaFabrizio Melfa
Fabrizio Melfa
Gabriele CirannaGabriele Ciranna
Gabriele Ciranna
Background and Clinical Significance: Iatrogenic atrophy following intralesional corticosteroid injections represents a rare but potentially disfiguring complication, particularly when administered in the facial region for the treatment of inflammatory acne. Unlike conventional post-acne atrophic scarring, corticosteroid-induced tissue loss involves both dermal and subcutaneous compartments, resulting in a clinically distinct presentation that poses significant therapeutic challenges, with no established consensus on optimal management. Case Presentation: We report the case of a 26-year-old Caucasian female (Fitzpatrick phototype III) presenting with severe iatrogenic facial atrophy of the left cheek, resulting from multiple intralesional corticosteroid injections performed by a previous physician for papulo-pustular acne. The condition had been clinically stable for approximately two years at first evaluation. The patient underwent a stepwise multimodal protocol delivered over approximately 18 months (November 2023 to April 2025), combining non-ablative fractional laser remodelling (LightScan—Eufoton), Autologous Regenerative Therapy (ART, Seffiller technique, Seffiline srl), hyperdiluted calcium hydroxylapatite (CaHA—Radiesse, Merz Aesthetics) biostimulation, and additional non-ablative fractional photothermolysis sessions, supported by a topical cosmeceutical protocol. Documented follow-up extended to December 2024, 13 months after the initiation of treatment at our centre. Clinician-assessed severity of the post-acne atrophic scarring component improved from Goodman & Baron Grade 3 to Grade 2. Global aesthetic improvement of the treated area was rated as +2 (“much improved”) on the GAIS, with a patient satisfaction score of 5/5. No validated grading instrument was applied to the subcutaneous volume deficit itself, for which no such instrument is currently available. Conclusions: This case documents the clinical management and favourable outcome of a patient with severe iatrogenic steroid-induced facial atrophy treated with a personalised multimodal protocol. While the observed improvement is encouraging, the single-case design does not permit conclusions regarding the efficacy, reproducibility, or generalisability of this approach. Future controlled studies are needed to determine the therapeutic value of this multimodal strategy for this rare condition.

23 April 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
Alessandro GennaiAlessandro Gennai
Alessandro Gennai
MBMonica Baldessin
Monica Baldessin
Fabrizio MelfaFabrizio Melfa
Fabrizio Melfa
BBBruno Bovani
Bruno Bovani
ACAlessandra Camporese
Alessandra Camporese
PTPiero Tesauro
Piero Tesauro
Background: The ageing process starts in the center of the face, in the periocular region and around the mouth, with a combination of volume loss and tissue descent, wrinkles deepen, and loss of skin structure and quality. Recently, several studies proved the efficacy of therapies based on the autologous adipose tissue grafting that leverages the properties of stromal vascular fraction (SVF) and adipose derived mesenchymal stem cells (ADSCs) to accelerate the regenerative processes of the skin. This study aimed to verify the ability of the guided Superficial Enhanced Fluid Fat Injection (SEFFI) in the facial area to correct volume loss and skin aging and proved the very low rate of complications of this standardized procedure . Methods: we retrospectively collected data from 2,365 procedures performed in Italian centers between 2019 and 2021. Guided SEFFI was performed alone or combined with cosmetic treatments, including the use of hyaluronic acid filler, suspension threads, synthetic calcium hydroxylapatite, botulin toxin, and microneedling. Results: SEFFI was used alone in more than 60% of the patients, and in all face areas. In about one tenth of patients SEFFI was combined with botulin toxin treatment or hyaluronic acid filling. Other procedures were used more rarely. Ecchymosis in the donor or injection sites was the most frequent event, and yet observed in only 14.2% and 38.6% of patients, respectively. Conclusions: The SEFFI technique is standardized and minimally invasive, leading to very few complications. It can be a promising antiaging medical treatment that combines effectiveness, safety, and simplicity.

14 January 2026 in Aesthetic Surgery Journal Open Forum
Verified
Journal Article
Open access
Fabrizio MelfaFabrizio Melfa
Fabrizio Melfa
ADAnastasia Dafne
Anastasia Dafne
Gabriele CirannaGabriele Ciranna
Gabriele Ciranna
MSMelfa Sonia
Melfa Sonia
GNGiovanni Nicoletti
Giovanni Nicoletti
Background: Current diagnostic tools for upper arm laxity assessment—including the pinch test and two-dimensional photographic scales—fail to characterize the underlying tissue composition, leading to inappropriate treatment selection and preventable complications. Objectives: To introduce the Melfa-Anastasia Arm Laxity System (MAALS), a precision medicine framework integrating high-frequency ultrasound (HFUS) biometry with a cylindrical geometric model for objective, compositional assessment of brachial architecture. Methods: MAALS employs a noncontact stand-off technique (HFUS, 18-22 MHz) to measure superficial adipose tissue thickness (SAT) and triceps muscle thickness (M) at the mid-brachial sentinel point. Two dimensionless indices are derived: the adipose saturation percentage (%SAT = SAT/Rtot × 100) and the muscle filling ratio (MFR = M/Rtot), where Rtot is the total brachial radius calculated from arm circumference. Results: Based on preliminary anatomically rational thresholds, MAALS defines five phenotypes (0-4): normotrophic (0), adipose hypertrophy (1), mixed morphology (2), pure cutaneous ptosis with critical vascular risk zone (%SAT < 20%, SAT < 4-5 mm; liposuction contraindicated) (3), and sarcopenic/atrophic (4). Each phenotype carries specific therapeutic indications ranging from prevention to regenerative strategies. Conclusions: MAALS is presented as a conceptual precision medicine framework requiring prospective validation, not as an established clinical standard. By providing objective compositional characterization of brachial architecture, it offers a structured basis for safer, more individualized treatment planning, future multicenter validation studies, and integration with AI-based segmentation technologies. Level of Evidence: 5 (Therapeutic):

26 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Fabrizio MelfaFabrizio Melfa
Fabrizio Melfa
Gabriele CirannaGabriele Ciranna
Gabriele Ciranna
Background and Clinical Significance: Iatrogenic atrophy following intralesional corticosteroid injections represents a rare but potentially disfiguring complication, particularly when administered in the facial region for the treatment of inflammatory acne. Unlike conventional post-acne atrophic scarring, corticosteroid-induced tissue loss involves both dermal and subcutaneous compartments, resulting in a clinically distinct presentation that poses significant therapeutic challenges, with no established consensus on optimal management. Case Presentation: We report the case of a 26-year-old Caucasian female (Fitzpatrick phototype III) presenting with severe iatrogenic facial atrophy of the left cheek, resulting from multiple intralesional corticosteroid injections performed by a previous physician for papulo-pustular acne. The condition had been clinically stable for approximately two years at first evaluation. The patient underwent a stepwise multimodal protocol over approximately 18 months, combining non-ablative fractional laser remodelling (LightScan – Eufoton), Autologous Regenerative Therapy (ART, Seffiller technique, Seffiline srl), hyperdiluted calcium hydroxylapatite (CaHA – Radiesse, Merz Aesthetics) biostimulation, and additional non-ablative fractional photothermolysis sessions, supported by a topical cosmeceutical protocol. Clinician-assessed scar severity improved from Goodman & Baron Grade 3 to Grade 2, and Vancouver Scar Scale score from 4–5/13 to 1–2/13. Global aesthetic improvement was rated as +2 ("Much improved") on the GAIS, with patient satisfaction of 5/5. Conclusions: This case demonstrates that a carefully sequenced multimodal approach combining energy-based devices, biological scaffolds, and biostimulatory agents can achieve substantial and durable correction of iatrogenic steroid-induced facial atrophy, providing a reproducible framework for managing this under-reported and therapeutically challenging condition.